We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
- Authors
Herold, K C; Gitelman, S E; Willi, S M; Gottlieb, P A; Waldron-Lynch, F; Devine, L; Sherr, J; Rosenthal, S M; Adi, S; Jalaludin, M Y; Michels, A W; Dziura, J; Bluestone, J A
- Abstract
Type 1 diabetes results from a chronic autoimmune process continuing for years after presentation. We tested whether treatment with teplizumab (a Fc receptor non-binding anti-CD3 monoclonal antibody), after the new-onset period, affects the decline in C-peptide production in individuals with type 1 diabetes.
- Publication
Diabetologia, 2013, Vol 56, Issue 2, p391
- ISSN
1432-0428
- Publication type
Journal Article
- DOI
10.1007/s00125-012-2753-4